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Genes containing an interferon (IFN)-stimulated re-
sponse element (ISRE) can be divided into two groups
according to their inducibility by IFN and virus infec-
tion: one induced only by IFN and the other induced by
both IFN and virus infection. Although it is now clear
that IFN regulatory factor 7 (IRF7) is a multifunctional
gene essential for induction of type I IFNs, regulation of
the IRF7 promoter (IRF7p) is poorly understood. The
IRF7 gene includes two IFN responsive elements, an
IRF-binding element (IRFE) in the promoter region and
an ISRE in the first intron, and is induced by the IFN-
triggered Jak-STAT pathway by binding of the IFN-stim-
ulated gene factor 3 (ISGF3) complex to the ISRE. In this
study, we demonstrate that IRF3 and IRF7, which with
the coactivators CREB-binding protein and P300 form
the virus-activated factor (VAF) complex upon Sendai
virus infection, bind to the IRF7 ISRE and IRFE and can
directly activate IRF7 transcription. Promoter reporter
assays show that both the ISRE and IRFE are responsive
to activation by IRF7 and IRF3. In cells transiently ex-
pressing IRF7 or/and IRF3, the VAF level and binding of
VAF are clearly increased after Sendai virus infection.
Studies with Jak1 kinase inactive 293 cells that were
stably transfected with a Jak1 kinase dead dominant
negative construct, and the mutant cell lines SAN
(IFN/), U2A (IRF9), U4A (Jak1), and DKO (IRF1/
IRF2) show that the IRF7 transcription activated di-
rectly by VAF is distinct from and independent of the
IFN signaling pathway. Thus, IRF7 transcription is au-
toregulated by binding of the IRF7-containing VAF to its
own ISRE and IRFE. The results show two distinct
mechanisms for the activation of the IRF7 promoter, by
IFN and by virus infection. A regulatory network be-
tween type I IFNs and IRF7 is proposed. The distinct
pathways may reflect special roles for an efficient anti-
viral response at different stages of virus infection.
In immune and inflammatory responses, virus infection re-
sults in activation or direct induction of a set of transcription
factors, the interferon (IFN)1 regulatory factors (IRFs), which
are a family involved in the regulation of IFNs and IFN induc-
ible genes. IFNs participate in antiviral defense, cell growth
regulation, and immune activation by inducing a set of IFN
inducible genes (1–5). IRF3 and IRF7 have been demonstrated
to play an essential role in virus-dependent signaling, whereas
IRF1, IRF-2, and IRF9 are critical for proper IFN-dependent
gene expression (6–9).
All cellular IRFs have an N-terminal DNA-binding domain
that is capable of binding to IFN-stimulated response elements
(ISREs) with the consensus sequence 5-(A/G)NGAAANN-
GAAACT-3 in the IFN gene promoters (6, 8–13). Besides IFN
genes, many other genes such as the tumor suppressor p53
(14), the transporter associated with antigen processing 2
(Tap2) (15), and the Epstein-Barr virus (EBV) latent mem-
brane oncoprotein 1 (LMP1) (16) possess ISRE motifs and are
regulated by IRFs. Because these genes are involved in cell
cycle regulation, apoptosis, and tumor suppression, IRFs are
also involved in regulation of these processes in addition to
their roles in immune regulation (17–19). Two such sequence
motifs, 5-GGAAAGCGAAACC-3 (ISRE) and 5-CAAAAGC-
GAAACT-3 (IRF-binding element, IRFE), have been identified
in the IRF7 first intron and in its promoter, respectively (20).
IRF7 has a wider DNA-binding specificity (GAAWNYG-
AAANY, W  A or T, Y  C or T) compared with IRF3
(GAAASSGAAANY, S  G or C) (21). Studies on murine IFNA
promoters showed that the core sequence GAAANN for IRF
binding can be divided into four groups according to the iden-
tity of the NN: 1, the NC (N  G, C, A, or T) and ST bases
inducible by both IRF3 and IRF7; 2, the NG and CA preferen-
tially responsive to IRF3; 3, the GAAAAT repeats responding
only to IRF7; and 4, the DA (D  T, A, or G) unresponsive to
both factors (7, 22). Interestingly, both the IRF7 ISRE and
IRFE match the first group, which is inducible by both IRF3
and IRF7.
The ISRE-containing genes are regulated by IRFs typically
through the Jak-STAT pathway. In this pathway, type I or II
IFN stimulation results in the phosphorylation of STAT1 and
STAT2. The phosphorylated STAT1 and STAT2, together with
IRF9, which is constitutively expressed in most cell types, form
the complex, interferon-stimulated gene factor 3 (ISGF3) (23).
This complex binds to the ISREs in the ISRE-containing genes
and activates their transcription. A single copy of ISRE is
sufficient for gene activation, but ISRE-containing genes are
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not inducible in mutant cell lines in which any Jak-STAT
pathway component has been knocked out (10, 24). Expression
of IRF7 is typically mediated by the IFN-triggered Jak-STAT
pathway in which ISGF3 directly binds to the IRF7 ISRE
(20, 25).
Although virus infection or synthetic double-stranded RNA
results in expression of type I IFNs, which induce expression of
IFN-inducible genes, some of these IFN-inducible genes (such
as ISG15/54/56) are also directly induced upon virus infection
or by double-stranded RNA independent of the IFN-triggered
Jak-STAT pathway (24, 26–30). The IRF family member, IRF1,
is also induced by both IFN and direct virus infection independ-
ent of IFN signaling (9, 31). Other IFN-inducible genes such as
ISG9–27 and ISG6–16, however, are only induced by IFNs but
not by virus infection or double-stranded RNA (3, 32). Thus, it
seems that virus infection and IFN trigger two distinct cellular
pathways, which sometimes converge on the same cis-acting
elements. The slight differences in the ISRE motifs in the
promoters of these ISRE-containing genes confer their different
specificity in inducibility by either IFN or virus through un-
known mechanisms (3).
IRF7 functions as either an activator or a repressor in
regulation of some ISRE-containing genes. In addition to
induction of type I IFN expression (33, 34), IRF7 also re-
presses EBNA1 transcription in EBV type III latency (35),
activates Tap2 transcription via EBV LMP1 (15), and induces
LMP1 expression (16).
Although extensive studies have shown that IRF7 is a mul-
tifunctional protein with transcriptional activity that depends
on C-terminal phosphorylation, regulation of the IRF7 pro-
moter (IRF7p) is poorly understood. Previous data show that
ISGF3 is a potent factor in the induction of IRF7 expression in
mouse (25) and human cells (20). In this study, in addition to
induction by type I IFNs, we demonstrate that IRF7 transcrip-
tion can be regulated by binding of both IRF7 and IRF3 pro-
teins in the virus-activated factor (VAF) complex to the IRF7p
ISRE and IRFE and that this regulation is independent of the
IFN pathway.
EXPERIMENTAL PROCEDURES
Plasmids—The IRF7 promoter construct p(1123/575)-Luc, which
contains the wild type ISRE and IRFE motifs as well as its three mutants,
IRFEm-Luc, (ISREIRFE)m-Luc, and ISRE-Luc, were gifts from Paul
Pitha (20). ISREm-Luc and IRFE-Luc were made by site-directed mu-
tation (Stratagene) using p(1123/575)-Luc as template. The IFN
promoter construct, pGL3/IFNp-Luc, was described previously (36). The
expression plasmids IRF7 (35), FLAG-IRF7 and its mutants (36), IRF3
and IRF3(5D), were described previously (29). The zinc inducible kinase
inactive Jak1 (Jak1 K896R) cDNA cloned in MTCB6 vector was kindly
provided by Paul Rothman (37). Both pMTCB6-Jak1DN and EGFP-C1
vector contain a neomycin resistance gene that allows transfected cells to
be selected using G418. FLAG-IRF7DN, FLAG-IRF3, FLAG-IRF3DN,
and FLAG-IRF3(5D) were constructed by subcloning corresponding PCR
products into pCMV2-FLAG vector (Sigma), which was kindly provided
by John Hiscott.
Cell Lines and Establishment of Stable Transfectants—293 cells are
derived from human kidney epithelial cells. HeLa cells are derived from
cervical carcinoma. Mutant cell lines, U2A cells lacking functional
IRF9, U4A cells lacking Jak1, and the parent cells 2fTGH (human
fibroblasts) were gifts from George Stark (10, 38), and SAN cells (hu-
man glioblastoma) lacking type I IFN genes were the gift of Marc
Wathelet and Tom Maniatis (39). The DKO cell line used in this study
is a mouse embryonic fibroblast line with targeted disruption of both
the IRF1 and IRF2 genes (40). All the cell lines were maintained in
Dulbecco’s modified Eagle’s medium plus 10% fetal bovine serum and
antibiotics.
293 cells were transfected with an Effectene kit following the man-
ufacturer’s instructions (Qiagen). Cells lines stably expressing 1) Jak1-
DN, 2) EGFP-C1, FLAG-IRF7DN, and FLAG-IRF3DN, and 3) Jak1-
DN, FLAG-IRF7DN, and FLAG-IRF3DN were generated. EGFP-C1
empty vector cotransfected in 2) was for selection with G418. Expres-
sion of Jak1-DN was induced by adding ZnCl2 at a final concentration
of 50 M for 8 h before G418 was added. One day after transfection, cells
were cultured in medium containing 800 g/ml of G418 (Invitrogen) for
2 weeks. Single stable clones were screened and expression of FLAG-
IRF7 and FLAG-IRF3 in some single clones was detected by Western
blot using anti-FLAG (Sigma). Stably expressing cells were maintained
in 400 g/ml G418-containing medium.
Reporter Assays—For luciferase assays, cells in 12-well plates were
transfected with 0.2 g of reporter plasmid and 0.1 g -galactosid-
ase expression plasmid with the use of an Effectene kit. After 12 h,
cells were infected with 200 HAU SeV for 24 h or IFN2 for 12 h after
transfection. Cell lysates were combined with Luciferase Assay Rea-
gent (Promega), and the relative light units were measured in an
Autolumat LB953 (PE, Inc.). The activity of -galactosidase was used
as internal control.
Electrophoretic Mobility Shift Assay (EMSA)—Cells in 60-mm dishes
were transfected with 2 g of expression plasmids with an Effectene kit.
42 h after transfection, cells were infected with 200 HAU/ml Cantell
Sendai viruses for 6 h before harvest (3). Cells were lysed in binding
buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 50 mM NaCl, 2 mM
dithiothreitol, 5% glycerol, 0.5% Nonidet P-40, 10 g/l bovine serum
albumin) with protease inhibitors. The whole cell lysates were used for
EMSA, as described previously (36). Poly(dI-dC) (Amersham Bio-
sciences) was added to reduce nonspecific binding at a final concentra-
tion of 62.5 g/ml. Probes with 5-GATC or 5-GTAC adhesive ends were
annealed and labeled with [-32P]dCTP in Klenow reactions. For each
binding reaction, about 40,000 cpm of probe were used. For supershift
assays, cell lysates were incubated with 0.2 g FLAG antibody M2
(Sigma), 2 g of IRF3 antibody SL-12 (BD Biosciences), CBP antibody
A-22, or p300 antibody N-15 (Santa Cruz Biotechnology) before probe
was added. ProteinDNA complexes were separated on 5% 60:1 acryl-
amide/bis-acrylamide gels.
Chromatin Immunoprecipitation Assay—HeLa cells in 100-mm
dishes were transfected with 5 g of expression plasmids or empty
vector. Cells were infected with SeV for 6 h and then subjected to
cross-linking by adding formaldehyde to a final concentration of 1% for
30 min at room temperature with slow rotation. Cross-linking was
stopped by adding glycine to a final concentration of 125 mM for 5 min.
Chromatin was sheared to 300 bp by sonication. Immunoprecipita-
tion, washing, and the recovery of bound DNA were performed following
the protocol provided by Upstate Biotechnology. After extraction and
precipitation, DNA pellets were dissolved in 60 l of H2O, and 15 l of
each were used for PCR. All PCR reactions were performed for 35 cycles
with a high fidelity PCR system (Roche Applied Science) at an anneal-
ing temperature of 60 °C. PCR products were run on 1.5% agarose gels.
RT-PCR—Cells were infected with 200 HAU/ml of SeV or 500 units/ml
IFN2 (Sigma) for indicated time periods. RT was performed for 60 min in
a volume of 20 l with 1 g of total RNA with an RT-PCR system kit
(Promega). The cDNA products were diluted 5 times. PCR was run in the
linear range (30 cycles) at an annealing temperature of 60 °C in a high
fidelity PCR system (Roche Applied Science). Primers for -actin were
5-GGCATCGTGATGGACTCCG-3 and 5-GCTGGAAGGTGGACAGC-
GA-3. PCR products were run on 1.5% agarose gels.
RESULTS
Virus Infection Induces Endogenous IRF7 mRNA—IRF7 pos-
sesses an ISRE and an IRFE in its promoter and first intron
(20). IRF3 and IRF7 can potentially bind to these elements
after activation by virus infection and therefore directly induce
expression of IRF7 independently of the Jak-STAT pathway.
To test this hypothesis, we first performed RT-PCR in SAN
cells lacking type I IFN genes and in 293 cells stably trans-
fected with a Jak1 kinase dominant negative construct
(pMTCB6/Jak1-DN). Total mRNAs were isolated for quanti-
tative RT-PCR for detection of IRF7 expression (41–45).
SAN cells were infected with SeV for the indicated time
periods (Fig. 1A). As shown in Fig. 1A, SeV infection increases
IRF7 mRNA detectable after 6 h, and further increases can be
detected up to 72 h. Because type II IFN (IFN ) is produced by
activated T-lymphocytes (T-cells) and natural killer cells (46,
47), the time course data from the human glioblastoma SAN
cells indicate that IRF7 can be induced by SeV infection inde-
pendently of type I and II IFNs.
Because the recently discovered IFN also induces an anti-
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viral state and expression of interferon-stimulated genes
(ISGs) and works through the Jak-STAT pathway (48, 49), we
used a Jak1 kinase dead, dominant negative stably transfected
293 cell line (293-Jak1DN) to exclude the possibility that SeV
induction of IRF7 involves IFN and/or the Jak1-STAT path-
way. Analysis of RNA from SeV-infected 293-Jak1DN cells
revealed a pattern of IRF-7 induction similar to that observed
in SAN cells (Fig. 1B). That the Jak1DN blocked endogenous
Jak1 activity was confirmed by examining the expression of the
ISG56 gene, a target of Jak1 signaling (50) (Fig. 1C, compare
lanes 3 and 4).
Also, we performed promoter reporter assays in 293 cells,
HeLa cells, and in several mutant cell lines, SAN (IFN/),
U2A (IRF9), U4A (Jak1), and DKO (IRF1/IRF2). The
results disclosed that IRF7 and IRF3 can activate a 1.6-kb
IRF7 promoter construct, p(1123/575)-Luc which contains
both the IRFE and ISRE, and SeV infection can increase the
IRF7 promoter activity significantly in these cells (data not
shown).
Thus, because Jak1 is required for signaling pathways trig-
gered by all IFNs including IFN / (type I), IFN (type II), and
IFN (10, 48, 49), the data from the mutant cell line SAN and
Jak1DN cells indicate that IRF7 can be induced by SeV infec-
tion independently of all types of IFNs.
IRF7 and IRF3 Are Required for SeV Infection-induced IRF7
Expression—Because SeV infection induced IRF7 expression
independently of IFNs, we next asked whether IRF7 and IRF3
are important for this induction. To answer this question we
generated 293 stable cell lines expressing 1) dominant negative
IRF7 (IRF7DN) and IRF3 (IRF3DN) (51) or 2) IRF7DN,
IRF3DN, and Jak1-DN. We infected these cells, the 293-
Jak1DN cells, and wild type 293 cells with SeV and analyzed
IRF-7 mRNA by RT-PCR. SeV infection of 293-Jak1DN cells
induced substantial amounts of IRF7 mRNA as expected (Fig.
2A, compare lanes 1 and 3). However, SeV infection did not
induce significant IRF7 expression in the cells expressing the
IRF3DN, IRF7DN, and Jak1DN mutants (Fig. 2A, compare
lanes 3 and 4). These results indicate that the induction of IRF7
by SeV requires IRF3 and IRF7 but does not require Jak1. In
contrast, in the absence of Jak1-DN, IFN treatment induced
IRF7 expression (Fig. 2A, compare lanes 5 and 7), and IRF3-DN
and IRF7-DN did not affect IRF7 levels (Fig. 2A, compare lanes
7 and 8), implying that IRF3 and IRF7 are not required for this
induction. IRF7 was not induced by IFN in the presence of
Jak1-DN (Fig. 2A, compare lanes 5 and 6), indicating that Jak1
is required for induction of IRF7 by IFN.
For the promoter reporter assays, the IRF7 promoter con-
struct p(1123/575)-Luc was transfected in these stably
transfected cells, and the cells were infected with SeV or
treated with IFN. Fig. 2B shows that SeV infection resulted in
a significant increase of IRF7 promoter reporter activity in cells
with or without Jak1 kinase activity. However, no significant
increase was detected in the presence of IRF3-DN and
IRF7-DN mutants. In contrast, IFN treatment resulted in
greater IRF7 promoter activity in the absence of Jak1-DN
regardless of the presence of IRF7-DN and IRF3-DN, but could
not activate the IRF7 promoter construct in cells transfected
with Jak1-DN. Thus, both the RT-PCR and promoter reporter
results show that IRF3 and IRF7 are required for the direct
induction of IRF7 by SeV infection.
Both IRFE and ISRE Contribute to IRF7 Promoter Activa-
tion—The ISRE but not the IRFE is responsive to IFN in
transient transfection assays (20). To check if both the ele-
ments are responsive to IRF7 and IRF3, we compared the
responses of a panel of mutants of p(1123/575)-Luc to tran-
siently expressed IRF7 and IRF3. The mutants are depicted in
Fig. 3A (20). Mutation in the ISRE core sequence (GG-
GAAAGCGAAACC to GGGAAAGCatAACC) or deletion of the
ISRE dramatically reduced the basal activity to 20% in empty
vector-transfected cells, but mutation in the IRFE core se-
quence (CAAAAGCGAAACT to CAAAAGCttAACT) or deletion
of the IRFE did not clearly affect the basal activity (Fig. 3B),
implying that the ISRE but not the IRFE may account for the
high constitutive activity. Similar to the wild type construct
p(1123/575)-Luc, activation was still detected with muta-
tion or deletion of either the ISRE or IRFE motif. However,
mutation in both the ISRE and IRFE led to complete loss of the
FIG. 1. Virus infection induces expression of endogenous IRF7
mRNA. SAN cells (IFN/) (A) and Jak1 kinase inactive 293 cells (B)
in 6-well plates were infected with 200 HAU/ml Cantell SeV for the
indicated times. The histogram at the top represents quantification of
the IRF7 mRNA intensity normalized to -actin mRNA intensity. Fold
is relative to the basal level of IRF7 mRNA in SAN cells. C, RT-PCR
results for ISG56 gene expression show the inactivity of Jak1 kinase in
these Jak1 kinase inactive 293 cells. Total RNA was extracted, and
equal amounts of total RNA were used to prepare cDNA. PCR was
performed with specific primers for IRF7 and -actin. Primers for
ISG56 are 5-CCAGCGCTGGGTATGCGATCTCTGCC-3 and 5-
GGGCCCGCTCATAGTACTCCAGGGC-3, and primers for IRF7 are
5-CGCGGCACTAACGACAGGCGAG-3 and 5-GCTGCCGTGCCC-
GGAATTCCAC-3.
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response to IRF3 and IRF7 (Fig. 3B). These data indicate that
both the ISRE and IRFE contribute to activation of IRF7p by
IRF3 and IRF7 but that the ISRE is chiefly responsible.
IRF3 and IRF7 Bind to the IRF7 Promoter as Constituents of
the Complex VAF—To show whether IRF7 and IRF3 bind di-
rectly to the ISRE and IRFE of IRF7p, EMSA was performed
with the use of synthesized IRF7p ISRE and IRFE as probes.
As shown in Fig. 4A, in vector-transfected cells no specific band
was detected (Fig. 4A, lane 1), but after virus infection a very
weak specific band appeared (Fig. 4A, lane 2). The specificity of
the band was demonstrated by competition assays with AP1
oligomers (data not shown). In all other cell lysates transfected
with IRF7 or IRF3 or both, more intense bands of the same size
were detected (Fig. 4A, lanes 3–10). The bands became much
stronger after SeV infection (Fig. 4A, lanes 4, 6, 8, and 10,
compared with lanes 3, 5, 7, and 9, respectively). An interesting
feature of the specific band detected by EMSA is that regard-
less of the plasmid(s) transfected and whether the cells were
infected with SeV, all of the bands are of the same size. Thus,
it is most likely that IRF7 and IRF3 bind to the ISRE as part of
the VAF complex in both uninfected and SeV-infected cells
because VAF forms upon virus infection and includes both
IRF3 and IRF7 (3).
To be sure that the bands represent VAFDNA complex, the
sample transfected with FLAG-IRF7 and IRF3 was subjected
to supershift analyses with antibodies against FLAG, IRF3,
p300, and CBP. The results show that besides containing just
IRF7 and IRF3 these bands also contain p300 and CBP (Fig.
4A, lanes 11, 12, 15, and 16). We also compared binding and
supershift of the VAF complex with the PRD31 probe from
FIG. 2. IRF3 and IRF7 but not Jak1
are required for induction of IRF7 by
SeV infection. A, 293 cells or Jak1 ki-
nase inactive 293 cells were infected with
200 HAU/ml SeV for 48 h or treated with
500 units/ml IFN2 (Sigma) for 12 h. To-
tal RNA was used for RT-PCR. Primers
for IRF7 are 5-ATGGCCTTGGCTCCTG-
AGAGGGCAGCCCC-3 and 5-GGGGG-
CCTGGGGCTTGGAGTCC-3. The IRF7
PCR product is located in the sequence
corresponding to the DNA-binding do-
main, which is absent in FLAG-IRF7DN.
B, 293 cells or 293 Jak1-DN stable cells
were transfected with 0.2 g of
p(1123/575)-Luc and 0.1 g of -ga-
lactosidase construct. After 12 h, cells
were infected with 200 HAU/ml SeV for
24 h or treated with IFN2 for 12 h. Rel-
ative light units were measured and
normalized by -galactosidase activities.
Reporter assay results are representa-
tive of two independent experiments, for
each of which two duplicates for each
sample were tested. Error bars represent
the mean  S.E. of the two duplicates. C,
expression of FLAG-IRF3DN and FLAG-
IRF7DN in stable cell lines expressing 1)
FLAG-IRF7DN, FLAG-IRF3DN, and EG-
FP-C1 and 2) FLAG-IRF7DN, FLAG-IR-
F3DN, and Jak1-DN.
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IFNp. As expected, for both the ISRE of IRF7p and PRD31 of
IFNp, the bands detected were the same size, were completely
shifted by FLAG antibody, and completely blocked by the IRF3
antibody. The CBP and p300 antibodies are not as robust but
still shifted most of the complex (Fig. 4B, lanes 3–10). The
polyclonal IRF7 antibody H-246 (Santa Cruz Biotechnology)
does not have access to IRF7 in this complex because it cannot
produce a shift. The increase of VAF binding may be caused by
virus-induced phosphorylation of IRF3 and IRF7, which results
in formation of more VAF complexes (3). Also, we found that
FIG. 3. Both the IRFE and ISRE contribute to IRF7 promoter activation by IRF7 and IRF3. A, reporter constructs of the 1.6-Kb IRF7
promoter and its mutants. B, HeLa cells in 12-well plates were transfected with expression plasmids IRF3 or IRF7 and the IRF7 promoter construct
p(1123/575)-Luc or a panel of its mutants, ISREm-Luc, IRFEm-Luc, (ISREIRFE)m-Luc, ISRE-Luc, and IRFE-Luc. Cells were harvested
after 24 h for luciferase and -galactosidase assays; -galactosidase activity was used as internal control. Experiments were repeated three times;
a typical result is shown. Error bars represent the mean  S.E. of the two duplicates in one experiment.
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both IRF7 and IRF3 can bind to the IRF7p IRFE (Fig. 4C).
Thus, these results indicate that IRF3 and IRF7 bind directly
to the IRF7p ISRE and IRFE as part of the complex VAF.
IRF7 and IRF3 Bind to the Endogenous IRF7 Promoter—The
promoter reporter, RT-PCR, and EMSA results suggested that
induction of IRF7 by SeV infection results from direct binding
of VAF to the endogenous IRF7 promoter, which is embedded in
chromatin. To confirm these observations, chromatin immuno-
precipitation assays were performed. HeLa cells were trans-
fected with the empty vector pCMV2-FLAG, FLAG-IRF7, or
FLAG-IRF3, separately, and the cells were infected with SeV.
Cell lysates were immunoprecipitated with monoclonal FLAG
antibody M2, and the precipitates were extensively washed.
PCR was performed with IRF7 ISRE- and IRFE-specific prim-
ers. As a positive control, PCR was also performed with IFN
virus responsive element (VRE)-specific primers. As shown in
Fig. 5, we detected a band using each of the paired primers in
FLAG-IRF7 or FLAG-IRF3 transfected cells after immunopre-
cipitation with FLAG antibody. This band is very weak or not
present in vector-transfected cells and in FLAG-IRF7 or FLAG-
IRF3 transfected cells, extracts of which were immunoprecipi-
tated with normal mouse IgG, indicating that it is specific and
that both IRF7 and IRF3 bind to either or both ISRE and IRFE
of the endogenous IRF7 promoter in addition to VRE of IFNp.
Because the promoter reporter assays (Fig. 3) show that IRF3
and IRF7 can activate IRF7 ISRE and IRFE reporter con-
structs separately and the EMSA results (Fig. 4) show that
IRF3 and IRF7 can bind to these two elements in vitro sepa-
rately, and we sheared the DNA to 300 bp, whereas these two
elements are 600 bp apart, it is most likely that IRF3 and
IRF7 bind to both the endogenous ISRE and IRFE elements.
DISCUSSION
Our results clearly show that IRF7 is a gene that can be
induced directly by binding of VAF to its ISRE and IRFE upon
SeV infection, and this induction is independent of the IFN-
triggered Jak-STAT pathway (Fig. 6A). Our previous reports
showed that EBV LMP1 can induce IRF7 expression through
an unknown mechanism in addition to promoting phosphoryl-
ation of IRF7 protein (52, 53). Also, tumor necrosis factor  has
been reported to induce IRF7 expression through activation of
NFB, which can bind to the NFB-binding site identified in
IRF7p (41). Besides these factors, IRF7 transcription is also
thought to be regulated by promoter methylation and chroma-
FIG. 4. VAF binds to the ISRE and IRFE of the IRF7 promoter. 293 cells in 60-mm dishes were transfected with 2 g of expression plasmids
as indicated. Cells were infected as indicated with 200 HAU/ml Cantell Sendai virus for 6 h before harvest. Cells were lysed in 60 l of lysis buffer.
10 l of whole cell lysate were used for each binding reaction. The synthesized double-stranded sequences containing IRF7 ISRE are 5-
GATCCTCCCGGGAAAGCGAAACCTAAACA-3 and 5-GATCTGTTTAGGTTTCGCTTTCCCGGGAG-3. The sequences containing IRF7 IRFE are
5-GTACGGTAACAAAAGCGAAACTCCATC-3 and 5-GATCGATGGAGTTTCGCTTTTGTTACC-3. The sequences containing IFN positive reg-
ulatory domain 31 (PRD31) are 5-GTACGAAAACTGAAAGGGAGAAGTGAAAGTG-3 and 5-GTACCACTTTCACTTCTCCCTTTCAGTTTTC-3.
The synthesized probes of IRF7p ISRE and IFNp PRD31 were radioactively labeled; 40,000 cpm were used for each reaction. For supershift
studies, 0.2 g of FLAG antibody M2 or 2 g of IRF3 antibody SL-12, CBP antibody A-22, or p300 antibody N-15 were incubated with the cell
lysates for 20 min before the probes were added. ProteinDNA complexes were separated on 5% 60:1 Acr/bis-Acr gels.
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tin accessibility based on the observations that reagents that
loosen chromatin structure are capable of enhancing IRF7 ex-
pression (41, 52). Thus, regulation of IRF7 transcription is
complex, and in addition to the identified functional ISRE,
IRFE, and NFB sites, there are many other potential tran-
scription factor-binding sites in the IRF7 promoter.
Although we show here that IRF7 and IRF3 bind to the ISRE
in the VAF complex, we cannot exclude the possibility that
monomers and homodimers of IRF7 or IRF3 are also involved
in the activation of IRF7p. In cells transfected with IRF7 alone
or IRF3 alone, we sometimes detected two specific bands in
EMSA, one of which ran faster than VAFDNA complex (data
not shown), suggesting that IRF7 or IRF3 homodimers may be
involved in IRF7 regulation. Also, previous reports have shown
that IRF3 or IRF7 homodimers are involved in the activation of
their target genes (36, 54). IRF7 homodimers form in the ab-
sence of phosphorylation (55). Like VAF, formation of IRF3
homodimers requires phosphorylation of IRF3 and association
with CBP/P300. IRF3 homodimers that form upon virus infec-
tion are even more stable than IRF3/IRF7 heterodimers (54).
FIG. 5. IRF7 and IRF3 bind to the
endogenous IRF7 promoter. HeLa
cells in 100-mm dishes were transfected
with 5 g of FLAG-IRF7, FLAG-IRF3, or
empty vector (EV). Cells were infected
with SeV for 6 h before harvest. Cross-
linking and chromatin immunoprecipita-
tion assays were performed as described
under “Experimental Procedures.” Inputs
were 5% of lysates of each sample. The
primers for amplifying IRF7p IRFE
(414/-128) were 5-CTCGGGAGGCTTA-
GGTAGGAG-3 and 5-CGGAGTAGGGA-
GGAGTGGAGG-3, for IRF7p ISRE
(28/292): 5-GTACTGGGGACCCCA-
GACCCAC-3 and 5-CTGCGGAGACGG-
GAAAGGCGAC-3, and for the VRE of




FIG. 6. A proposed regulatory net-
work between IFN/ and IRF7. A,
virus infection activates IRF7 transcrip-
tion independently of IFN signaling. Vi-
rus-induced formation of VAF binds to the
IRF7 ISRE and IRFE and directly induces
IRF7 transcription independently of IFN-
triggered signaling. B, two regulatory cir-
cuits between IFN/ and IRF7. (1) Virus
infection results in phosphorylated IRF3
and IRF7, which form the VAF complex
by recruiting CBP and P300. VAF binds
to the VRE in the IFN promoter and
strongly induces the expression of IFN
(3). IFN (type I or type II) induces the
phosphorylation of STAT1 and STAT2
that results in the formation of ISGF3
(23), an efficient inducer of IRF7 expres-
sion, by binding directly to the IRF7 ISRE
(20, 25, 43). (2) VAF upon virus infection
also binds to IRF7 ISRE and IRFE and
activates IRF7 transcription.
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These data imply that VAF may not be the only form that
transactivates the IRF7 promoter. The possible presence of
IRF7 or IRF3 homodimers may depend on the balance of IRF3
and IRF7 protein molecules. In cells transfected with IRF7
alone, IRF7 protein is present in greater amount than IRF3
protein, and so IRF7 homodimers probably form in addition to
formation of VAF with IRF3 in response to virus infection (3).
Building on previous data on type I IFN regulation and IRF7
regulation, we propose a regulatory network between type I
IFNs and IRF7 (Fig. 6B). This network includes two positive
regulatory circuits. 1) VAF upon virus infection binds directly
to the VRE of the IFN promoter and strongly induces IFN
production (3). This pathway plays a central role in host-cell
immune responses to virus infection (3, 56). Later, it was re-
ported that IFN-triggered ISGF3 is an efficient inducer for
IRF7 expression by binding directly to the IRF7 promoter (20,
25, 43) as confirmed in RT-PCR results (data not shown). 2) In
this study, we found that IRF7 transcription is activated inde-
pendently of circuit 1 by binding of VAF to IRF7 ISRE and
IRFE. Thus, virus infection results in two distinct pathways:
one leads to the IFN signaling pathway, and the other leads to
direct induction of IRF7. However, because virus infection only
results in weak activation of the IRF7 promoter but very strong
activation of the IFN/ promoters, virus infection is primarily
responsible for IFN/ induction.
The present results show that IRF7, like other IFN inducible
genes such as ISG15/54/56 (24, 26–29), is inducible by virus
infection independent of IFN signaling. Induction of ISRE-
containing genes by either IFNs or both IFNs and virus
through different pathways requires different IRF family mem-
bers: the IFN signaling pathway involves IRF9, and the IFN-
independent pathway activated by virus infection requires
IRF3 and IRF7. The biological significance of the distinct path-
ways is obscure, but they do not perform redundant functions,
may complement each other for an efficient antiviral response
(30, 57, 58), and may reflect distinct requirements at different
stages during virus infection. In addition, in contrast to IRF3,
which is constitutively expressed in all cell types and is induc-
ible neither by IFNs nor upon virus infection (59), IRF7 is not
constitutively expressed in most cell types. Thus, the autoreg-
ulation of IRF7 may function to ensure that there is sufficient
IRF7 for an efficient antiviral response.
Finally, these findings may impinge on the role of IRF7 in
latent EBV infection. We have reported that IRF7 can induce
the endogenous LMP1 promoter via its ISRE and restore LMP1
protein levels in a deficient cell line P3HR1 (16). The circuit
proposed here may also indirectly affect levels of this important
viral oncoprotein.
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